Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 11/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24492890 | 0.91 | PDK2 (0.59) | PDK2CYP19A1CYP2A6PGRCYP17A1 | |
| SCHEMBL12865732 | 0.90 | PDK2 (0.60) | PDK2CYP19A1CYP2A6PGRCYP17A1 | |
| SCHEMBL22428446 | 0.89 | PDK2 (0.43) | PDK2 | |
| SCHEMBL22428443 | 0.89 | PDK2 (0.56) | PDK2CYP19A1CYP2A6PGRCYP17A1 | |
| SCHEMBL22414197 | 0.89 | PDK2 (0.59) | PDK2CYP19A1CYP2A6CYP17A1CYP11B1 | |
| SCHEMBL9973675 | 0.89 | CYP2A6 (0.51) | PDK2CYP19A1CYP2A6PGRCYP17A1 | |
| SCHEMBL12259758 | 0.88 | PDK2 (0.47) | PDK2CYP19A1CYP2A6PGRCYP17A1 | |
| SCHEMBL24492817 | 0.88 | PDK2 (0.49) | PDK2 | |
| SCHEMBL24493207 | 0.88 | PDK2 (0.55) | PDK2CYP19A1CYP2A6PGRCYP17A1 | |
| SCHEMBL22037443 | 0.87 | PDK2 (0.47) | PDK2CYP19A1CYP2A6PGRCYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177454-A1 | TRISUBSTITUTED BENZENE COMPOUND HAVING NITROGEN-CONTAINING HETERO RING IN MOLECULAR TERMINUS AND ORGANIC ELECTROLUMINESCENCE ELEMENT | HODOGAYA CHEMICAL CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| WO-2020184379-A1 | TRISUBSTITUTED BENZENE COMPOUND HAVING NITROGEN-CONTAINING HETERO RING IN MOLECULAR TERMINUS AND ORGANIC ELECTROLUMINESCENCE ELEMENT | 保土谷化学工業株式会社 | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177454-A1 | TRISUBSTITUTED BENZENE COMPOUND HAVING NITROGEN-CONTAINING HETERO RING IN MOLECULAR TERMINUS AND ORGANIC ELECTROLUMINESCENCE ELEMENT | ETV6, LEF1, TEAD2 | PDK2 3784/4885CYP19A1 2451/4885CYP2A6 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.